Clinical trial · Observational
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
ERKENTNIS: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
NCT01400854CI-TRIAL-00008331ERKENTNIScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Effentora® | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Effentora®
- description
- Single group prospective treatment cohort
- interventionNames
- Drug: Effentora®
Primary outcomes (1)
- measure
- pain relief
- timeFrame
- 4 weeks
- description
- to show adequate pain relief within 10 minutes
Secondary outcomes (4)
- measure
- occurrence of adverse events
- timeFrame
- 4 weeks
- description
- document the tolerability of Effentora®
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * decision to start treatment with Effentora * prescription in accordance with Summary of Product Characteristics (SmPC) * personally signed and dated Informed Consent document Exclusion Criteria: * any subject considered unsuitable according to SmPC
References
Publications (0)
Data not yet available
No reference posted for this study.